Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Snynf crawled time : 13:00 save search
IGM Biosciences Announces Refocusing of Sanofi Collaboration
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.0%
H: 0.19%
C: -0.47%
IGMS | News | $8.13 -11.63% -13.58% 250K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: -13.23%
collaboration sanofi
AstraZeneca Expands Fasenra’s Label to Younger Children with Severe Asthma
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: 0.0%
label children astrazeneca
Sanofi Agrees to Settle 4,000 Zantac Cancer Lawsuits in US State Courts
Published: 2024-04-04 (Crawled : 13:00) - biospace.com/
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.18%
H: 0.0%
C: 0.0%
state cancer sanofi
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-29 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
ADAG | $2.53 -6.3% -0.37% 11K
|
Manufacturing
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
year update financial results
Exscientia Business and Financial Update for the Full Year 2023
Published: 2024-03-21 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: 0.14%
H: 0.24%
C: 0.24%
EXAI | $4.32 1.65% 1.62% 270K
|
|
| O: -3.35%
H: 0.0%
C: -7.39%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
business year update financial
Constellation Appoints New Chief Financial Officer, Daniel Bisgeier
Published: 2024-03-14 (Crawled : 13:00) - prnewswire.com
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
financial
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-13 (Crawled : 13:00) - biospace.com/
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
SGMO | $0.516 -4.8% -5.65% 1.2M
|
Health Technology
|
| O: 2.19%
H: 4.55%
C: -10.78%
business year therapeutics financial results
BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications
Published: 2024-03-05 (Crawled : 13:00) - prnewswire.com
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
patent japan international
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1594 6.34% 5.19% 2M
|
Health Technology
|
| O: -3.69%
H: 4.0%
C: -0.58%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
tnx-1500 pharmaceuticals preclinical
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
MLTX | $43.51 0.02% 0.06% 270K
|
|
| O: 0.51%
H: 0.86%
C: -4.53%
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
nanobody meeting trial
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
MLTX | $43.51 0.02% 0.06% 270K
|
|
| O: 1.3%
H: 0.0%
C: -16.18%
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -1.6%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
day business year financial
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1594 6.34% 5.19% 2M
|
Health Technology
|
| O: 3.26%
H: 2.37%
C: -1.53%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
tnx-1500 pharmaceuticals trial
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Published: 2024-02-27 (Crawled : 13:00) - globenewswire.com
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
DNLI | $16.82 -3.0% -3.15% 960K
|
Health Technology
|
| O: 18.06%
H: 17.95%
C: 17.1%
business year therapeutics financial results
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MLTX | $43.51 0.02% 0.06% 270K
|
|
| O: 0.0%
H: 2.86%
C: 0.13%
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
nanobody fda positive ema program
Sanofi, Denali ALS Candidate Flops in Mid-Stage Trial
Published: 2024-02-19 (Crawled : 13:00) - biospace.com/
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
candidate als trial
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
Published: 2024-02-15 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
potential therapy show
Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
therapeutics
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
financial
Resalis Therapeutics Appoints Almut Nitsche as Chief Medical and Development Officer
Published: 2024-02-01 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -4.37%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -5.26%
H: 0.0%
C: 0.0%
medical therapeutics
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
MDGL M | $228.34 -1.99% -1.98% 250K
|
Health Technology
|
| O: 0.08%
H: 0.92%
C: 0.37%
pharmaceuticals
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.